MapLight Therapeutics

News

MapLight Therapeutics has made its debut on the Nasdaq, raising $251m for a lead drug that could be a rival to BMS' new schizophrenia drug Cobenfy.

News

BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.